心力衰竭中的口腔与肠道微生物组改变:流行病学、发病机制及对晚期心衰治疗的反应
本综述更新了消化道微生物组改变、炎症与氧化应激关联心衰发病与进展的数据,描述了左心室辅助装置(LVAD)和心脏移植(HT)后这些关系的演变,并概述了可调控微生物组、可能改变心衰病程的现有与未来干预策略。
要点
- 观察性研究一致显示消化道微生物组改变与炎症及心衰风险和进展相关。
- LVAD和HT后微生物扰动持续存在,并伴随残余炎症和氧化应激。
- 微生物组对HT后免疫抑制药物代谢的贡献日益受到认识。
核心结论
- 微生物组改变、系统性炎症与心脏替代治疗前后心衰患者不良结局之间可能存在机制联系。
研究设计与样本
- 综述,检索范围未在摘要中报告。
主要发现
- 观察性研究一致表明消化道(肠道和口腔)微生物组改变与炎症及心衰风险和进展相关。
- 近期数据表明LVAD和HT后这些微生物扰动持续存在,并伴有残余炎症和氧化应激。
- 微生物组对HT后免疫抑制药物代谢的关键贡献日益受到认识。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite significant advances in therapies, heart failure (HF) remains a progressive disease that, once advanced, is associated with significant death and disability. Cardiac replacement therapies with left ventricular assist device (LVAD) and heart transplantation (HT) are the only treatment options for advanced HF, while lifesaving they can also be lifespan limiting due to the associated complications. Systemic inflammation is mechanistically important in HF pathophysiology and progression. However, directly targeting inflammation in HF has not been beneficial thus far. These failed attempts at therapeutics might be related to our limited understanding of the factors that cause inflammation in HF, and, therefore, to our inability to investigate these triggers in interventional studies. Observational studies have consistently demonstrated associations between alterations in the digestive (gut and oral) microbiome, inflammation and HF risk and progression. Additionally, recent data indicate that these microbial perturbations persist following LVAD and HT, along with residual inflammation and oxidative stress. Furthermore, there is rising recognition of the critical contribution of the microbiome to the metabolism of immunosuppressive drugs after HT. Cumulatively, these findings might posit a mechanistic link between microbiome alterations, systemic inflammation, and adverse outcomes in HF patients before and after cardiac replacement therapies. This review (1) provides an update on available data linking changes in digestive tract microbiota, inflammation, and oxidative stress, to HF pathogenesis and progression; (2) describes evolution of these relationships following LVAD and HT; and (3) outlines present and future intervention strategies that can manipulate the microbiome and possibly modify HF disease trajectory.
引用
- Yuzefpolskaya M, Bohn B, Ladanyi A, et al. Oral and gut microbiome alterations in heart failure: Epidemiology, pathogenesis and response to advanced heart failure therapies. J Heart Lung Transplant. 2022. PMID: 36586790. doi:10.1016/j.healun.2022.12.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。